Biosimilars Market by Product (Recombinant Glycosylated Proteins (Monoclonal Antibodies (Rituximab, Adalimumab, and Infliximab), Erythropoietin, and Follitropin), Recombinant Non-Glycosylated Proteins (Insulin, Granulocyte Colony Stimulating Factor, Recombinant Human Growth Hormone and Interferon (Interferon-Alpha and Interferon-Beta)), Recombinant Peptides (Glucagon and Calcitonin)), Type of Manufacturing (In-house Manufacturing, and Contract Manufacturing), Disease (Chronic Disease , Oncology, Autoimmune Disease, Blood disorders, Infectious Diseases, and Growth Hormone Deficiency) - Global Forecast to 2030

Report ID : 67  |  Published Date : Apr 2019  |  Pages : 150  |  Region : Global  |  Report Code : PH-2





Biosimilars Market by Product (Recombinant Glycosylated Proteins (Monoclonal Antibodies (Rituximab, Adalimumab, and Infliximab), Erythropoietin, and Follitropin), Recombinant Non-Glycosylated Proteins (Insulin, Granulocyte Colony Stimulating Factor, Recombinant Human Growth Hormone and Interferon (Interferon-Alpha and Interferon-Beta)), Recombinant Peptides (Glucagon and Calcitonin)), Type of Manufacturing (In-house Manufacturing, and Contract Manufacturing), Disease (Chronic Disease , Oncology, Autoimmune Disease, Blood disorders, Infectious Diseases, and Growth Hormone Deficiency) - Global Forecast to 2030